Panagora Asset Management’s Pacira BioSciences PCRX Stock Holding History

Panagora Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,225	Closed	-$927K	–	2916
2021 Q1	$927K	Sell	13,225 -43,442	-77%	-$3.1M	0.01%	1050
2020 Q4	$3.39M	Buy	56,667 +12,051	+27%	+$706K	0.02%	533
2020 Q3	$2.68M	Sell	44,616 -32,328	-42%	-$1.88M	0.02%	540
2020 Q2	$4.04M	Hold	76,944	–	–	0.03%	456
2020 Q1	$2.58M	Hold	76,944	–	–	0.02%	522
2019 Q4	$3.49M	Hold	76,944	–	–	0.02%	597
2019 Q3	$2.93M	Hold	76,944	–	–	0.01%	619
2019 Q2	$3.35M	Sell	76,944 -25,544	-25%	-$1.08M	0.02%	624
2019 Q1	$3.9M	Buy	102,488 +85,787	+514%	+$3.35M	0.02%	590
2018 Q4	$718K	Buy	+16,701	New	+$780K	﹤0.01%	1206
2016 Q2	–	Sell	-606	Closed	-$32K	–	2336
2016 Q1	$32K	Buy	+606	New	+$35.4K	﹤0.01%	2081
2015 Q3	–	Sell	-1,879	Closed	-$133K	–	2406
2015 Q2	$133K	Hold	1,879	–	–	﹤0.01%	1861
2015 Q1	$167K	Hold	1,879	–	–	﹤0.01%	1745
2014 Q4	$167K	Buy	+1,879	New	+$178K	﹤0.01%	1685

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Panagora Asset Management's PCRX Position: Q2 2021 in Review

Panagora Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2021, closing a stake of 13,225 shares — an estimated $927K sold.

Panagora Asset Management first reported a position in PCRX in Q4 2014 and held it in 14 quarters. The position peaked at $4.04M in Q2 2020. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

Panagora Asset Management reported no remaining Pacira BioSciences position as of Q2 2021 after selling out during the quarter.
Panagora Asset Management sold 13,225 Pacira BioSciences shares in Q2 2021, an estimated $927K.
Panagora Asset Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 14 quarters.
Panagora Asset Management's Pacira BioSciences position peaked at $4.04M in Q2 2020.
262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.